{"id":4441,"date":"2020-05-22T09:57:04","date_gmt":"2020-05-22T09:57:04","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=4441"},"modified":"2025-11-26T14:50:38","modified_gmt":"2025-11-26T12:50:38","slug":"maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/","title":{"rendered":"黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications"},"content":{"rendered":"<p><strong>Lyon, France, May 12, 2020<\/strong> \u2013 黑料社 announced today the appointment of leading international experts in the field of microbiome research, hemato-oncology, infectiology, immunology, pharmacology, and clinical trial methodology to its newly-formed Scientific Advisory Board (SAB) focused on the treatment of Graft versus Host Disease (GvHD). The SAB will serve as a resource to advise 黑料社 on its scientific, regulatory and clinical development strategies supporting the further clinical evaluation of its microbiome restoration biotherapeutics in hemato-oncology indications as well as the expansion into solid tumor indications.\u201c黑料社 is spearheading a new class of microbiome-based therapeutics in oncology and has identified an area of unmet therapeutic need with steroid-refractory acute GvHD, where its products can be beneficial for patients with limited treatment options,\u201d commented Ernst Holler, MD, PhD, newly elected Chair of 黑料社\u2019s SAB. \u201cResearch and initial clinical evidence have demonstrated that the microbiome can be a potent modulator of cancer treatment efficacy. I am delighted to work with this group of internationally-recognized scientific and clinical experts as well as with the 黑料社 team to help guide the company as it continues to advance its pipeline.\u201d\u201cIt is an honor to bring together these esteemed experts to support the progression of our microbiome restoration biotherapeutics toward late-stage clinical development,\u201d added Herv\u00e9 Affagard, co-founder and CEO of 黑料社. \u201cWe look forward to drawing on their expertise as we advance our product candidates and initiate plans to evaluate the oral formulation of our full ecosystem microbiota therapeutic in acute myeloid leukemia patients. The capsule, MaaT033, will also give us the opportunity to enter new oncological indications in the future, including combination treatment regimens with immune checkpoint inhibitors.\u201dThe inaugural voting members of 黑料社\u2019s SAB are listed below. Biographies for each member can also be found on the 黑料社 website.<strong>Ernst Holler, MD, PhD<\/strong><br \/>\nErnst Holler was Director of the Clinical and Experimental Allogeneic Stem Cell Transplant Program in the Department of Internal Medicine at the University of Regensburg, Germany, for more than 20 years and is now Senior Professor on Translational Research in GvHD. With more than 250 peer-reviewed manuscripts to his name, he is an expert in the field of Graft versus Host Disease and was awarded the van Bekkum Award, the highest award from the European Society for Stem Cell Transplantation.<strong>Madan Jagasia, MD<\/strong><br \/>\nMadan Jagasia is Professor of Medicine in Hemato-oncology and Chief Medical Officer at the Vanderbilt-Ingram Cancer Center in Nashville, TN. As a clinical investigator with over 20 years of experience, his primary research interest is GvHD and is the site\u2019s principal investigator for the national US chronic GvHD consortium.<strong>Robert Jenq, MD<\/strong><br \/>\nRobert Jenq is an Assistant Professor and Deputy Department Chair at the Department of Genomic Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. His research uses a multidisciplinary approach to examine the impact of the microbiome on cancer treatment particularly on bone marrow transplantation and cancer immunotherapies.<strong>Florent Malard, MD, PhD<\/strong><br \/>\nFlorent Malard is a hematologist at the Hospital Saint-Antoine and an Associate Professor at Sorbonne University in Paris, France. His research includes clinical and translational studies on allogeneic hematopoietic stem cell transplantation with a particular focus on preclinical studies on GvHD and has published over 100 peer-reviewed manuscripts.<strong>Robert Zeiser, MD<\/strong><br \/>\nRobert Zeiser is Head of the Section for Tumor Immunology and Immune Modulation at the Medical Center of the University of Freiburg in Germany. His research focuses on haematology, oncology, and hematopoietic stem cell transplantation. He has received several awards for his outstanding achievements in clinical therapeutic drug research.<\/p>\n<h3><em>About 黑料社<\/em><\/h3>\n<p>黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, 黑料社 has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lyon, France, May 12, 2020 \u2013 黑料社 announced today the appointment of leading international experts in the field of microbiome research, hemato-oncology, infectiology, immunology, pharmacology, and clinical trial methodology to its newly-formed Scientific Advisory Board (SAB) focused on the treatment of Graft versus Host Disease (GvHD). The SAB will serve as a resource to advise 黑料社 on its scientific, regulatory and clinical development strategies supporting the further clinical evaluation of its microbiome restoration biotherapeutics in hemato-oncology indications as well as the expansion into solid tumor indications.\u201c黑料社 is spearheading a new class of microbiome-based therapeutics in oncology and has identified an area of unmet therapeutic need with steroid-refractory acute GvHD, where its products can be beneficial for patients with limited treatment options,\u201d commented Ernst Holler, MD, PhD, newly elected Chair of 黑料社\u2019s SAB. \u201cResearch and initial clinical evidence have demonstrated that the microbiome can be a potent modulator of cancer treatment efficacy. I am delighted to work with this group of internationally-recognized scientific and clinical experts as well as with the 黑料社 team to help guide the company as it continues to advance its pipeline.\u201d\u201cIt is an honor to bring together these esteemed experts to support the progression of our microbiome restoration biotherapeutics toward late-stage clinical development,\u201d added Herv\u00e9 Affagard, co-founder and CEO of 黑料社. \u201cWe look forward to drawing on their expertise as we advance our product candidates and initiate plans to evaluate the oral formulation of our full ecosystem microbiota therapeutic in acute myeloid leukemia patients. The capsule, MaaT033, will also give us the opportunity to enter new oncological indications in the future, including combination treatment regimens with immune checkpoint inhibitors.\u201dThe inaugural voting members of 黑料社\u2019s SAB are listed below. Biographies for each member can also be found on the 黑料社 website.Ernst Holler, MD, PhD Ernst Holler was Director of the Clinical and Experimental Allogeneic Stem Cell Transplant Program in the Department of Internal Medicine at the University of Regensburg, Germany, for more than 20 years and is now Senior Professor on Translational Research in GvHD. With more than 250 peer-reviewed manuscripts to his name, he is an expert in the field of Graft versus Host Disease and was awarded the van Bekkum Award, the highest award from the European Society for Stem Cell Transplantation.Madan Jagasia, MD Madan Jagasia is Professor of Medicine in Hemato-oncology and Chief Medical Officer at the Vanderbilt-Ingram Cancer Center in Nashville, TN. As a clinical investigator with over 20 years of experience, his primary research interest is GvHD and is the site\u2019s principal investigator for the national US chronic GvHD consortium.Robert Jenq, MD Robert Jenq is an Assistant Professor and Deputy Department Chair at the Department of Genomic Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. His research uses a multidisciplinary approach to examine the impact of the microbiome on cancer treatment particularly on bone marrow transplantation and cancer immunotherapies.Florent Malard, MD, PhD Florent Malard is a hematologist at the Hospital Saint-Antoine and an Associate Professor at Sorbonne University in Paris, France. His research includes clinical and translational studies on allogeneic hematopoietic stem cell transplantation with a particular focus on preclinical studies on GvHD and has published over 100 peer-reviewed manuscripts.Robert Zeiser, MD Robert Zeiser is Head of the Section for Tumor Immunology and Immune Modulation at the Medical Center of the University of Freiburg in Germany. His research focuses on haematology, oncology, and hematopoietic stem cell transplantation. He has received several awards for his outstanding achievements in clinical therapeutic drug research. About 黑料社 黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, 黑料社 has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.<\/p>\n","protected":false},"author":2,"featured_media":4333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[50],"class_list":["post-4441","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-fr","year_press-50"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications - 黑料社<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications - 黑料社\" \/>\n<meta property=\"og:description\" content=\"Lyon, France, May 12, 2020 \u2013 黑料社 announced today the appointment of leading international experts in the field of microbiome research, hemato-oncology, infectiology, immunology, pharmacology, and clinical trial methodology to its newly-formed Scientific Advisory Board (SAB) focused on the treatment of Graft versus Host Disease (GvHD). The SAB will serve as a resource to advise 黑料社 on its scientific, regulatory and clinical development strategies supporting the further clinical evaluation of its microbiome restoration biotherapeutics in hemato-oncology indications as well as the expansion into solid tumor indications.\u201c黑料社 is spearheading a new class of microbiome-based therapeutics in oncology and has identified an area of unmet therapeutic need with steroid-refractory acute GvHD, where its products can be beneficial for patients with limited treatment options,\u201d commented Ernst Holler, MD, PhD, newly elected Chair of 黑料社\u2019s SAB. \u201cResearch and initial clinical evidence have demonstrated that the microbiome can be a potent modulator of cancer treatment efficacy. I am delighted to work with this group of internationally-recognized scientific and clinical experts as well as with the 黑料社 team to help guide the company as it continues to advance its pipeline.\u201d\u201cIt is an honor to bring together these esteemed experts to support the progression of our microbiome restoration biotherapeutics toward late-stage clinical development,\u201d added Herv\u00e9 Affagard, co-founder and CEO of 黑料社. \u201cWe look forward to drawing on their expertise as we advance our product candidates and initiate plans to evaluate the oral formulation of our full ecosystem microbiota therapeutic in acute myeloid leukemia patients. The capsule, MaaT033, will also give us the opportunity to enter new oncological indications in the future, including combination treatment regimens with immune checkpoint inhibitors.\u201dThe inaugural voting members of 黑料社\u2019s SAB are listed below. Biographies for each member can also be found on the 黑料社 website.Ernst Holler, MD, PhD Ernst Holler was Director of the Clinical and Experimental Allogeneic Stem Cell Transplant Program in the Department of Internal Medicine at the University of Regensburg, Germany, for more than 20 years and is now Senior Professor on Translational Research in GvHD. With more than 250 peer-reviewed manuscripts to his name, he is an expert in the field of Graft versus Host Disease and was awarded the van Bekkum Award, the highest award from the European Society for Stem Cell Transplantation.Madan Jagasia, MD Madan Jagasia is Professor of Medicine in Hemato-oncology and Chief Medical Officer at the Vanderbilt-Ingram Cancer Center in Nashville, TN. As a clinical investigator with over 20 years of experience, his primary research interest is GvHD and is the site\u2019s principal investigator for the national US chronic GvHD consortium.Robert Jenq, MD Robert Jenq is an Assistant Professor and Deputy Department Chair at the Department of Genomic Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. His research uses a multidisciplinary approach to examine the impact of the microbiome on cancer treatment particularly on bone marrow transplantation and cancer immunotherapies.Florent Malard, MD, PhD Florent Malard is a hematologist at the Hospital Saint-Antoine and an Associate Professor at Sorbonne University in Paris, France. His research includes clinical and translational studies on allogeneic hematopoietic stem cell transplantation with a particular focus on preclinical studies on GvHD and has published over 100 peer-reviewed manuscripts.Robert Zeiser, MD Robert Zeiser is Head of the Section for Tumor Immunology and Immune Modulation at the Medical Center of the University of Freiburg in Germany. His research focuses on haematology, oncology, and hematopoietic stem cell transplantation. He has received several awards for his outstanding achievements in clinical therapeutic drug research. About 黑料社 黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, 黑料社 has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/\" \/>\n<meta property=\"og:site_name\" content=\"黑料社\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-22T09:57:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T12:50:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"黑料社\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"黑料社\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/\"},\"author\":{\"name\":\"黑料社\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications\",\"datePublished\":\"2020-05-22T09:57:04+00:00\",\"dateModified\":\"2025-11-26T12:50:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/\"},\"wordCount\":747,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/\",\"name\":\"黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications - 黑料社\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"datePublished\":\"2020-05-22T09:57:04+00:00\",\"dateModified\":\"2025-11-26T12:50:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"黑料社\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"黑料社\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications - 黑料社","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/","og_locale":"fr_FR","og_type":"article","og_title":"黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications - 黑料社","og_description":"Lyon, France, May 12, 2020 \u2013 黑料社 announced today the appointment of leading international experts in the field of microbiome research, hemato-oncology, infectiology, immunology, pharmacology, and clinical trial methodology to its newly-formed Scientific Advisory Board (SAB) focused on the treatment of Graft versus Host Disease (GvHD). The SAB will serve as a resource to advise 黑料社 on its scientific, regulatory and clinical development strategies supporting the further clinical evaluation of its microbiome restoration biotherapeutics in hemato-oncology indications as well as the expansion into solid tumor indications.\u201c黑料社 is spearheading a new class of microbiome-based therapeutics in oncology and has identified an area of unmet therapeutic need with steroid-refractory acute GvHD, where its products can be beneficial for patients with limited treatment options,\u201d commented Ernst Holler, MD, PhD, newly elected Chair of 黑料社\u2019s SAB. \u201cResearch and initial clinical evidence have demonstrated that the microbiome can be a potent modulator of cancer treatment efficacy. I am delighted to work with this group of internationally-recognized scientific and clinical experts as well as with the 黑料社 team to help guide the company as it continues to advance its pipeline.\u201d\u201cIt is an honor to bring together these esteemed experts to support the progression of our microbiome restoration biotherapeutics toward late-stage clinical development,\u201d added Herv\u00e9 Affagard, co-founder and CEO of 黑料社. \u201cWe look forward to drawing on their expertise as we advance our product candidates and initiate plans to evaluate the oral formulation of our full ecosystem microbiota therapeutic in acute myeloid leukemia patients. The capsule, MaaT033, will also give us the opportunity to enter new oncological indications in the future, including combination treatment regimens with immune checkpoint inhibitors.\u201dThe inaugural voting members of 黑料社\u2019s SAB are listed below. Biographies for each member can also be found on the 黑料社 website.Ernst Holler, MD, PhD Ernst Holler was Director of the Clinical and Experimental Allogeneic Stem Cell Transplant Program in the Department of Internal Medicine at the University of Regensburg, Germany, for more than 20 years and is now Senior Professor on Translational Research in GvHD. With more than 250 peer-reviewed manuscripts to his name, he is an expert in the field of Graft versus Host Disease and was awarded the van Bekkum Award, the highest award from the European Society for Stem Cell Transplantation.Madan Jagasia, MD Madan Jagasia is Professor of Medicine in Hemato-oncology and Chief Medical Officer at the Vanderbilt-Ingram Cancer Center in Nashville, TN. As a clinical investigator with over 20 years of experience, his primary research interest is GvHD and is the site\u2019s principal investigator for the national US chronic GvHD consortium.Robert Jenq, MD Robert Jenq is an Assistant Professor and Deputy Department Chair at the Department of Genomic Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. His research uses a multidisciplinary approach to examine the impact of the microbiome on cancer treatment particularly on bone marrow transplantation and cancer immunotherapies.Florent Malard, MD, PhD Florent Malard is a hematologist at the Hospital Saint-Antoine and an Associate Professor at Sorbonne University in Paris, France. His research includes clinical and translational studies on allogeneic hematopoietic stem cell transplantation with a particular focus on preclinical studies on GvHD and has published over 100 peer-reviewed manuscripts.Robert Zeiser, MD Robert Zeiser is Head of the Section for Tumor Immunology and Immune Modulation at the Medical Center of the University of Freiburg in Germany. His research focuses on haematology, oncology, and hematopoietic stem cell transplantation. He has received several awards for his outstanding achievements in clinical therapeutic drug research. About 黑料社 黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, 黑料社 has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.","og_url":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/","og_site_name":"黑料社","article_published_time":"2020-05-22T09:57:04+00:00","article_modified_time":"2025-11-26T12:50:38+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","type":"image\/jpeg"}],"author":"黑料社","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"黑料社","Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/"},"author":{"name":"黑料社","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications","datePublished":"2020-05-22T09:57:04+00:00","dateModified":"2025-11-26T12:50:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/"},"wordCount":747,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/","url":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/","name":"黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications - 黑料社","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","datePublished":"2020-05-22T09:57:04+00:00","dateModified":"2025-11-26T12:50:38+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-formation-of-its-gvhd-focused-scientific-advisory-board-to-support-development-of-microbiome-restoration-therapeutics-in-hemato-oncological-indications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/"},{"@type":"ListItem","position":2,"name":"黑料社 Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"黑料社","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"黑料社"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4441"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4441\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/4333"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4441"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=4441"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=4441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}